Subcutaneous tanezumab 2.5 MG or 5 MG for patients with osteoarthritis of the knee or hip: onset and maintenance of efficacy over 24 weeks

Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab

“…Tanezumab's onset of effect in Studies 1 and 2 has been examined previously, based on the first time point where mean change (from baseline) in WOMAC score was significantly greater in the tanezumab arms than in the placebo arm. Onset of effect for all tanezumab arms was estimated at 2 weeks for all WOMAC domains assessed (Study 1: Pain and Physical Function; Study 2: Pain, Physical Function, and Stiffness) [ 12 , 26 ]. Improvements over placebo were evident at most (Study 1) or all (Study 2) time points up to the end of the treatment, but there were no formal criteria for defining sustained improvement as in the current analysis [ 12 , 26 ].…”

“…Onset of effect for all tanezumab arms was estimated at 2 weeks for all WOMAC domains assessed (Study 1: Pain and Physical Function; Study 2: Pain, Physical Function, and Stiffness) [ 12 , 26 ]. Improvements over placebo were evident at most (Study 1) or all (Study 2) time points up to the end of the treatment, but there were no formal criteria for defining sustained improvement as in the current analysis [ 12 , 26 ]. Our findings from Study 1 are in general agreement with these previous results in that we also observed onset of improvement in all WOMAC domains in the tanezumab arms within a few weeks of initiating treatment; median time to first improvement was 2 weeks for the 30% threshold and 4 weeks for the 50% threshold.…”

Relative Efficacy and Safety of Tanezumab for Osteoarthritis

“…After removing duplicates, we assessed 129 studies and excluded 106 studies based on the titles and abstracts. We assessed the full text of 26 possibly eligible papers, and excluded studies included 12 conference abstracts, [15][16][17][18][19][20][21][22][23][24][25][26] 3 papers with an insufficient sample size, [27][28][29] 1 duplicate study, 30 1 not relevant study, 31 and 1 incomplete study. 32 Finally, we included 8 eligible papers (9 studies) in the quantitative analysis and meta-analysis.…”